ReviewJournal of the American Society of Nephrology : JASN2018
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.
Review in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 5 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Evolving epidemiology and improving safety of rechallenge in immune checkpoint inhibitor-associated acute kidney injury: an updated meta-analysis.Frontiers in immunology · 2026Pooled it
- Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.International journal of clinical oncology · 2023Guideline
- Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis.World journal of urology · 2023Pooled it
- Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Secondary Membranous Nephropathy. A Narrative Review.Frontiers in medicine · 2020Pooled it
- Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy.Hepatology forum · 2026Article
- Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors.Renal failure · 2025Article
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.Clinical kidney journal · 2025Review
- Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies.Frontiers in oncology · 2025Article
- The differentiation and intervention strategies for acute kidney injury after or induced by immune checkpoint inhibitors.American journal of cancer research · 2025Review
- Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade.Nature communications · 2024Article
- Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.Renal failure · 2024Article
- Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2024Review
- Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes.Clinical kidney journal · 2024Article
- Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review.Journal of clinical medicine · 2024Article
- Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies.OncoTargets and therapy · 2024Review
- Exploring the Potential Role of Phytopharmaceuticals in Alleviating Toxicities of Chemotherapeutic Agents.Current protein & peptide science · 2024Review
- Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events.Frontiers in immunology · 2024Review
- Immune checkpoint inhibitors and acute kidney injury.Frontiers in immunology · 2024Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical practice, such that the subfield of "onco-nephrology" has emerged. Conventional chemotherapeutic drugs and novel agents targeting specific genes/proteins are effective cancer therapies but suffer from a number of adverse kidney effects. An effective avenue of cancer treatment is immunotherapy, which uses drugs that augment immune system-mediated recognition and targeting of tumor cells. As such, leveraging the immune system to target malignant cells represents an important modality in eradicating cancer. IFN and high-dose IL-2 are older immunotherapies used in clinical practice to treat various malignancies, whereas new cancer immunotherapies have emerged over the past decade that offer even more effective treatment options. The immune checkpoint inhibitors are an exciting addition to the cancer immunotherapy armamentarium. Chimeric antigen receptor T cells are also a new immunotherapy used to treat various hematologic malignancies. However, as with the conventional and targeted cancer agents, the immunotherapies are also associated with immune-related adverse effects, which includes nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.